

Thomas W. Wainwright and Tikki Immins

Background and History of ERAS in Orthopedic Surgery

The systematic implementation of an evidence-based perioperative care pathway—an enhanced recovery after surgery (ERAS) pathway (also known as fast-track)—has demonstrated that hospital length of stay and complications can be reduced, without increasing readmissions [1]. The first orthopedic surgeries to use ERAS pathways were total hip arthroplasty (THA) and total knee arthroplasty (TKA). These surgeries were chosen as they were both high volume, had long hospital length of stays, and carried high costs. ERAS pathways were first widely adopted in countries such as Denmark and the United Kingdom (UK) [2–5] through the use of centrally organized improvement programs. Their success led to their spread internationally, and their use is now broadly accepted as best practice for hip and knee arthroplasty surgeries (Fig. 49.1).

ERAS pathways aim to reduce a patient's recovery time following surgery and improve patient outcomes. To do this, orthopedic ERAS pathways encourage the patient to be active in the process of their recovery. Multidisciplinary teams focus on combining the evidence-based clinical steps with the required process and system changes, so that care is consistent for each patient. Logistical processes as well as clinical steps are optimized for each patient, so that postoperative recovery is quickened and complications, adverse events, and morbidity are reduced.

The overarching principles of an orthopedic ERAS pathway can be divided into four stages. At the preoperative stage, the focus is on optimization of preoperative health (such as the management of anemia and the promotion of smoking cessation), preoperative education and

counseling, and the preemptive organization of discharge arrangements. Intraoperatively, atraumatic surgical techniques are used; anesthesia and analgesia protocols are optimized; multimodal opioid-sparing analgesia regimes are adopted; blood loss is spared; normovolemia and normothermia are promoted; and hypoxia is prevented. Postoperatively, early ambulation is encouraged; effective analgesia is given, avoiding opioids where feasible; catheters, drains, and drips are not used or removed as soon as possible; and patients are encouraged to eat and drink early and wash, dress, and socialize as soon as possible. All patients are discharged home, using agreed criteria managed by the multidisciplinary team, with clear instructions and support on progressing independently. The details of effective ERAS programs have been previously reported [2].

ERAS pathways have been so successful in reducing length of stay that there is now growing evidence to suggest that outpatient surgery for THA and TKA is feasible for selected patients. A recent prospective study [6] found that of 557 unselected patients who were referred for surgery, actual discharge on the day of surgery occurred for 13–15%. Fifty-four percent had been identified as potentially being eligible for outpatient surgery. Twenty-eight percent of THA patients who had been identified as being eligible went on to have outpatient surgery, along with 24% of identified TKA patients. It was noted that 25% of those originally identified as being eligible for outpatient surgery could not be discharged on the same day as they had no adult available to stay with them for more than 24 hours following discharge. The most common reasons for not being discharged were lack of motivation, not fulfilling discharge criteria, and inability to mobilize safely.

Two recent systematic reviews [7, 8] also suggest that outpatient arthroplasty can be a safe and effective procedure for carefully selected patients; however, more research is required in order to critically examine its safety and potential cost savings.

T. W. Wainwright (✉) · T. Immins
Orthopaedic Research Institute, Bournemouth University,
Bournemouth, Dorset, UK
e-mail: twainwright@bournemouth.ac.uk




Fig. 49.1 ERAS general principles for hip and knee arthroplasty. PONV postoperative nausea and vomiting

74 **ERAS in Total Hip Arthroplasty and Total**
75 **Knee Arthroplasty**

76 **Clinical Outcomes**

77 ERAS has been reported to improve the quality of care for
78 patients in orthopedic surgery across a range of quality out-
79 come measures, and it should be remembered that fast-track
80 and ERAS protocols have always been based on the concept
81 of “first better – then faster.” Quality in healthcare is com-
82 plex and multifaceted; however, the six dimensions through
83 which the overall concept of quality is usually expressed
84 (safety, effectiveness, patient-centeredness, timeliness, effi-
85 ciency, and equity) can all be argued to have been improved
86 through the implementation of ERAS within THA and TKA
87 pathways.

88 **Length of Stay, Readmissions,**
89 **and Complications**

90 Total hip arthroplasty (THA) and total knee arthroplasty
91 (TKA) are common major surgical procedures often per-
92 formed in older patients with complex comorbidities. ERAS
93 has evolved during the past 20 years and has been shown to

94 be effective in reducing length of hospital stay (LOS) from
95 4–12 days to 1–3 days [9, 10] without increasing complica-
96 tions or readmission rates or compromising patient safety
97 [11]. In one of the most comprehensive reports of readmis-
98 sions post ERAS in hip and knee arthroplasty, Husted et al.
99 [2] found that in fast-track protocols, there was no increase
100 in readmission rates and complications, such as dislocation
101 after THA and reduced range of motion after TKA requiring
102 manipulation.

103 The literature has been consistent in finding that readmis-
104 sions do not increase following the implementation of ERAS;
105 however, studies should be read carefully to ensure classifi-
106 cation of readmissions is provided. In addition, the compari-
107 son of readmission rates after ERAS between different
108 countries and institutions is difficult because readmissions
109 may be classified differently. For example, a suspected deep
110 vein thrombosis (DVT) patient may be admitted to hospital
111 in some hospital systems or seen as an outpatient in others.
112 Some patient groups are still more likely to be readmitted
113 than others, even with ERAS; for example, a study of 2734
114 hip arthroplasty patients on a fast-track pathway found that
115 patients aged 75 and over, and with pharmacologically
116 treated psychiatric disease, were at an increased risk of dis-
117 location [12]. In another study, the same research group con-
118 cluded that surgery-related falls and subsequent readmission

94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118

119 after both hip and knee arthroplasty were related to patient
120 characteristics rather than the fast-track pathway [13].

121 **Mortality**

122 Historically, mortality rates in hip and knee arthroplasty sur-
123 geries are relatively low, but the implementation of ERAS
124 has been found to further reduce mortality rates. A large and
125 well-conducted UK study comparing 3000 unselected
126 ERAS patients with 3000 who had been on a traditional pro-
127 tocol reported reductions in mortality [10]. Mortality at
128 30 days and at 90 days was 0.1% and 0.5%, respectively, as
129 compared to 0.5% and 0.8% when patients were on a tradi-
130 tional protocol ($p = 0.03$ and $p = 0.1$). A follow-up to this
131 study [14] reported a mortality rate of 2.7% at 2 years, com-
132 pared to 3.8% for those on the traditional protocol ($p = 0.05$).
133 The authors suggest that a reduced stress response, shorter
134 length of stay (LOS), and improved pain control for the
135 ERAS cohort may have contributed to this lower rate.
136 Importantly, in another large study of THA and TKA
137 patients in Denmark, in which more than 17,000 on an
138 ERAS pathway were compared to nearly 62,000 on a tradi-
139 tional pathway, no increase in mortality was found follow-
140 ing ERAS, although this study fell short of proving a
141 decrease in mortality within 90 days of surgery [11].

142 **Patient-Reported Measures**

143 Patient-reported outcome measures (PROMs) and patient-
144 reported experience measures (PREMs) are considered an
145 important patient-centered measure of quality within ERAS
146 pathways [15, 16]. In the United Kingdom, hospitals are now
147 required to collect PROMs for all primary total hip and knee
148 arthroplasty patients as part of a national monitoring pro-
149 gram. In the United Kingdom, the measures used comprise
150 generic (e.g., EQ5D-5 L, EQ-VAS) and condition-specific
151 measures (e.g., Oxford hip and knee scores).

152 A systematic review of patient-generated data following
153 orthopedic surgery [17] for patients on an ERAS pathway
154 found a lack of data. Their review included data on 2208
155 THR and TKR patients, from 8 papers. Six of the papers
156 reported on patient satisfaction and found that scores were
157 high and not affected by length of stay. Quality of life,
158 reported in two papers, continued to increase following sur-
159 gery for up to 12 months; however, one paper highlighted
160 problems for patients in gaining necessary support
161 post-discharge.

162 There are, however, issues in using PROMs as an out-
163 come when assessing function. In a recent study of 80
164 patients [18], no correlation was found between objectively
165 assessed function and improvements found using PROMs at

14 days post-surgery for THA patients and at 21 days post- 166
surgery for TKA patients. While PROMs had improved fol- 167
lowing surgery, functional ability was decreased when 168
objectively assessed using the 40 m paced walk test, a 30s 169
chair stand test, and a 9-step stair-climb test and by an acti- 170
graphy recording of the level of activity. Consequently, in the 171
future, objective functional data will be increasingly impor- 172
tant from both a population and economic perspective, given 173
the known increased healthcare costs and lower income lev- 174
els of patients after THA and TKA [19], especially in light of 175
recent research that has found little evidence that physical 176
activity increases following TKA or THA [20–22]. 177

Economics 178

Economic considerations are important when considering 179
THA and TKA. They have been quoted to be two of the 180
most successful operations and hence are being performed 181
with increasing volume year-on-year around the world in 182
order to reduce pain and improve function [23]. Although 183
ERAS pathways have been shown to reduce LOS without 184
increasing complications and readmissions, few studies 185
have investigated the cost-effectiveness of implementing 186
these protocols. A systematic review evaluating the cost- 187
effectiveness of ERAS across a variety of surgical special- 188
ties concluded that ERAS protocols appeared to be 189
cost-effective in the short term; however, data on costs post- 190
discharge were lacking [24]. 191

A study in Denmark [25] used a time-driven activity- 192
based costing method to analyze time consumed by different 193
staff members involved in the treatment of THA and TKA 194
patients on ERAS pathways at two different hospitals. They 195
found costs (excluding the prosthesis) of \$2511 for THA and 196
\$2551 for TKA. Although these costs were not directly com- 197
parable to those published for more conventional pathways 198
[26, 27] due to differences in process and logistics, impor- 199
tantly the ERAS pathways were cheaper. 200

Implementation 201

ERAS pathways have been shown to safely reduce length of 202
stay to between 1 and 3 days, and outpatient surgery is now 203
possible in unselected patients [6]. However, despite this 204
there is evidence that only 40% of hospitals detail ERAS in 205
patient information leaflets for THA and TKA [28], suggest- 206
ing that adoption of the practice may not be complete. 207
Therefore, in addition to further examine how to optimize the 208
pathophysiological challenges that may affect early patient 209
recovery, the present state of the implementation of ERAS in 210
clinical practice should be considered. This is pertinent, 211
because in order to achieve the goal of a “pain- and risk-free 212

213 surgery,” we need to combine clinical evidence with imple- 237
 214 mentation in order to do “the right things right” (Fig. 49.2). 238
 215 However, despite the established evidence-based and wide- 239
 216 spread acceptance of ERAS for THA and TKA principles 240
 217 over the last 20 years, mean LOS for both THA and TKA is 241
 218 still greater than 4 days in a socialized health system such as 242
 219 the National Health Service (NHS) in the United Kingdom 243
 220 [29]. The reasons that may underpin the slow adoption of 244
 221 ERAS have been previously described [30] and include a lack 245
 222 of understanding, a lack of acceptance, a lack of ability, no 246
 223 organizational will to change, deficient leadership, and poor 247
 224 audit mechanisms. Therefore, the immediate challenge for 248
 225 health systems such as the NHS to improve surgical outcomes 249
 226 is a quality improvement one, where efforts to implement 250
 227 what is already known should be prioritized given the 251
 228 improvement seen in clinical outcomes with ERAS.

229 **The Development of ERAS® Society Guidelines**
 230 **for Hip and Knee Arthroplasty**

231 Over the last 15 years, the systematic implementation of 252
 232 ERAS pathways has shown that hospital LOS and complica- 253
 233 tions can be reduced [1] for a number of surgical procedures 254
 234 and ERAS protocols have been published for rectal, urologi- 255
 235 cal, pancreatic, gastric, breast and reconstructive, head and 256
 236 neck cancer, bariatric, and liver surgery [31–38]. 257

For hip and knee arthroplasty, up until now there have 237
 only been narrative reviews on fast-track/enhanced recovery 238
 protocols [39–41], and a systematic and evidence-based 239
 guideline has not been produced. Therefore, the ERAS® 240
 Society has recently brought together a group of interna- 241
 tional ERAS experts, in order to produce ERAS® Society 242
 recommendations for hip and knee arthroplasty. These rec- 243
 ommendations [42, 43] represent an extremely important 244
 document in summarizing the large volume of heterogeneous 245
 studies across all ERAS components within hip and knee 246
 arthroplasty surgery. The recommendations are detailed in 247
 Table 49.1 and are represented schematically in Fig. 49.2. 248
 Many of the principles are consistent with the core principles 249
 of ERAS in other surgical procedures. 250

These guidelines include a total of 17 topic areas. Best 251
 practice includes optimizing preoperative patient education, 252
 anesthetic technique, and transfusion strategy, in combina- 253
 tion with an opioid-sparing multimodal analgesic approach 254
 and early ambulation. There is insufficient evidence to rec- 255
 ommend that one surgical technique (type of approach, use 256
 of a minimally invasive technique, prosthesis choice, or use 257
 of computer-assisted surgery) over another will independ- 258
 ently effect achievement of discharge criteria. The guide- 259
 lines are consistent with other ERAS surgical procedures in 260
 recommending the limitation of fasting preoperatively, along 261
 with intraoperative optimization of fluid management, main- 262
 tenance of normothermia, and prophylactic treatment for 263




Fig. 49.2 ERAS in hip and knee replacement (THA and TKA): Recommendations for future development. EBM evidenced-based medicine, QI quality improvement, PROMs patient-reported outcome measures, Out-pt outpatient

Table 49.1 ERAS® Society recommendations for hip and knee arthroplasty

Number	Item	Recommendation	Evidence level	Recommendation grade
1	Preoperative information education and counseling	Patients should routinely receive preoperative education	Low	Strong
2	Preoperative optimization	4 weeks or more smoking cessation is recommended prior to surgery. Alcohol cessation programs are recommended for alcohol abusers	Smoking: high Alcohol: low	Strong
		Anemia should be actively identified, investigated, and corrected preoperatively	High	
3	Preoperative fasting	Clear fluids should be allowed up to 2 h and solids up to 6 h hours prior to induction of anesthesia	Moderate	Strong
4	Standard anesthetic protocol	General anesthesia and neuroaxial techniques may both be used as part of multimodal anesthetic regimes	General anesthesia: moderate	Strong
			Neuroaxial techniques: moderate	
5	Use of local anesthetics for infiltration analgesia and nerve blocks	Within a multimodal opioid-sparing analgesic regimen, the routine use of LIA is recommended for knee replacement but not for hip replacement. Nerve block techniques have not shown clinical superiority over LIA	LIA in knee replacement: high	Strong
6	Postoperative nausea and vomiting	Patients should be screened for and given multimodal PONV prophylaxis and treatment	Moderate	Strong
7	Prevention of perioperative blood loss	Tranexamic acid is recommended to reduce perioperative blood loss and the requirement for postoperative allogenic blood transfusion	High	Strong
8	Perioperative oral analgesia	A multimodal opioid-sparing approach to analgesia should be adopted. The routine use of paracetamol and NSAIDs is recommended for patients without contraindications	Paracetamol: Moderate	Strong
			NSAIDs: High	Strong
9	Maintaining normothermia	Normal body temperature should be maintained peri- and postoperatively	High	Strong
10	Antimicrobial prophylaxis	Patients should receive systemic antimicrobial prophylaxis	Moderate	Strong
11	Antithrombotic prophylaxis treatment	Patients are at increased risk of VTE and should undergo pharmacologic and mechanical prophylaxis in line with local policy	Moderate	Strong
			Moderate	
12	Perioperative surgical factors	Surgeons are recommended to use a proven prosthesis and surgical approach	High	Strong
13	Perioperative fluid management	A fluid balance should be maintained to avoid over- and under-hydration	Moderate	Strong
14	Postoperative nutritional care	An early return to normal diet should be promoted	Low	Strong
15	Early mobilization	Patients should be mobilized as early as they are able in order to facilitate early achievement of discharge criteria	Moderate	Strong
16	Criteria-based discharge	A team-based functional discharge criteria should be used to facilitate patient discharge directly to their home	Low	Strong
17	Continuous improvement and audit	The routine audit of process measures, clinical outcomes, cost-effectiveness, patient satisfaction/experience, and changes to the pathway is recommended	Low	Strong
			Low	

LIA local infiltration analgesia, PONV postoperative nausea and vomiting, VTE venous thromboembolism

infection and thrombosis. Postoperatively, in addition to early mobilization, early oral feeding is recommended. The published guidelines [43] will provide a detailed narrative review of all of the current literature and explain why certain components have been included and why other elements are not currently recommended.

The recommendations provide a starting point for implementation for teams new to ERAS and as a point of reflection for experienced ERAS teams to examine their current practice. These guidelines and the testing of their implementa-

tion, as has been performed in other ERAS procedures, will hopefully allow us to consolidate consensus within the evidence base, and generate new evidence, through systematic prospective data collection and through clinical trials.

Future Directions for Research

Future research for ERAS in hip and knee arthroplasty should focus on reaching the goal of the “pain- and risk-free”

281 hip and knee arthroplasty [44]. In order to do this, we need to
 282 better understand the pathophysiological mechanisms of
 283 recovery and the potential to optimize post-discharge func-
 284 tional outcomes [45]. This will be important because for
 285 some of the ERAS components, there is a strong need for
 286 properly designed randomized controlled studies that are
 287 sufficiently powered and performed in ERAS settings and
 288 that allow for discrimination between outcome parameters.

289 More specifically, it has been identified by Wainwright
 290 and Kehlet [45] that future trials should examine the preop-
 291 erative prediction of high-inflammatory responders, with
 292 further dose-finding or repeat-dosing glucocorticoid or other
 293 anti-inflammatory agents in studies in high-inflammatory
 294 responders [46] as well as more specific studies on high-pain
 295 responders (preoperative opioid users, pain catastrophizers,
 296 sensitized patients, etc.) [47].

297 In addition, work is still required in order to understand
 298 how to reduce impairment of physical activity and improve
 299 function quicker postoperatively; how to better identify
 300 patients at high risk of complications owing to psychiatric
 301 disorders, chronic renal failure, and orthostatic intolerance;
 302 anemia and transfusion thresholds; postoperative urine reten-
 303 tion and urinary bladder catheterization; and how to improve
 304 sleep. Intertwined with this will be the need for further
 305 research on the feasibility of same-day surgery and the type,
 306 timing, and duration of physiotherapy post-discharge [45,
 307 48]. The future directions recommended for research are
 308 summarized within Fig. 49.2 along with the recognized
 309 implementation factors identified earlier in the chapter.

310 ERAS in Other Orthopedic Procedures

311 Given the excellent outcomes for ERAS in hip and knee
 312 arthroplasty patients, it would therefore seem prudent to
 313 apply ERAS to every orthopedic procedure so that all ortho-
 314 pedic patients may benefit from the approach. Given the high
 315 volumes of orthopedic procedures, there is significant scope
 316 to improve patient outcomes and also significantly increase
 317 hospital productivity if ERAS pathways are implemented
 318 more widely. The staff involved in treating and looking after
 319 joint arthroplasty patients are often the same teams that care
 320 for all other types of orthopedic patients. Therefore, it should
 321 be relatively straightforward to achieve strong commitment
 322 and “buy-in” from these people to change the pathway and
 323 improve patient outcomes for other procedures.

324 Fractured Neck of Femur

325 Despite the fact that fractured neck of femur (FNOF) is an
 326 emergency procedure, given the similarities to primary and
 327 revision hip arthroplasty and the substantial scope for

328 improvement, the application of ERAS to this population
 329 demands attention. The National Hip Fracture Database
 330 reports that in 2016 more than 65,000 people were treated for
 331 hip fracture in England, Wales, and Northern Ireland. A
 332 study of NHS Trusts in England from November 2013 to
 333 October 2014 found that LOS for NHS Trusts ranged from
 334 12.3 days to 33.7 days, even though predicted LOS for these
 335 NHS Trusts, when adjusted for case mix, only ranged from
 336 21.5 to 24.4 days [49]. Other studies have also found signifi-
 337 cant variation in practice in the treatment and care of trauma
 338 patients [50, 51]. Wainwright et al. [49] contend that the
 339 introduction of an adapted and FNOF procedure-specific
 340 ERAS pathway could reduce variations in practice and there-
 341 fore overall LOS.

342 As with other orthopedic procedures, pain is a major con-
 343 tributor to delayed mobilization and recovery in FNOF
 344 patients, and Wainwright et al. [49] highlighted the role that
 345 peripheral nerve blocks may have in this pathway. A recent
 346 Cochrane Review found that compared with other modes of
 347 analgesia, peripheral nerve blocks used to treat FNOF reduce
 348 pain on movement better within 30 minutes, the risk of post-
 349 operative pneumonia is reduced, there is a reduced time to
 350 first mobilization after hip fracture surgery (approximately
 351 11 hours earlier), and the use of a peripheral nerve block
 352 given as a single injection leads to a reduced cost of analgesic
 353 drugs [52].

354 A further study in New Zealand [53] supports the imple-
 355 mentation of ERAS for this patient cohort, showing that
 356 overall LOS reduced for FNOF patients by 4 days after the
 357 introduction of an ERAS pathway. Time in the emergency
 358 department was reduced by 30 minutes, and the overall time
 359 in rehabilitation reduced by 3–7 days depending on the type
 360 of facility, so that patients spent 95 hours less in hospital than
 361 a comparable group on a conventional pathway in the 3 years
 362 prior to the ERAS pathway introduction. The FNOF-specific
 363 ERAS pathway focused on full interdisciplinary involve-
 364 ment. Orthopedic assessment was encouraged on the ortho-
 365 pedic ward that specialized in FNOF management, rather
 366 than in the emergency department, and every possible
 367 attempt was made to operate on the patient either that day or
 368 the following morning. Outstanding investigations were pri-
 369 oritized so that patients could proceed to surgery quickly. It
 370 was agreed that all patients should be suitable for rehabilita-
 371 tion and weight bearing 48 hours following surgery. The
 372 rehabilitation team was multidisciplinary, comprising nurses,
 373 medical, occupational therapists, physiotherapists, and social
 374 workers. Electronic data on the management of the patients
 375 was available in real time and was analyzed by staff on a
 376 weekly basis so that cross-functional teams could explore
 377 process issues and agree on actions to continue to improve
 378 clinical outcomes. A second study by Haugan et al. [54] in
 379 Norway, comparing 1032 FNOF patients on an ERAS proto-
 380 col to 788 on a conventional pathway, found no differences

381 between the groups in mortality and readmission within
382 365 days after the initial hospital admission. LOS was also
383 reduced by 3.4 days in the ERAS group.

384 The findings of these initial studies on using ERAS path-
385 ways in FNOF are encouraging. If the success of implement-
386 ing ERAS in elective pathways can be reproduced in FNOF
387 pathways, this would have a big impact on health systems in
388 terms of resources and cost economics and help to reduce
389 some of the capacity and economic pressures on these
390 systems.

391 Shoulder Arthroplasty

392 Total shoulder arthroplasty (TSA) is becoming increasingly
393 popular, with the United States (US) reporting an increase in
394 procedure rates of 319% between 1993 and 2007 [55]. As
395 yet, there are few studies reporting on ERAS concepts being
396 applied to TSA. An examination of Hospital Episode
397 Statistics [56] from April 2015 to March 2016 found that
398 NHS Trusts in England had LOS that varied from 1.0 to
399 6.4 days for TSA [57]. Expected case mix-adjusted LOS
400 ranged from 10.0 to 3.9 days, thereby suggesting that there is
401 scope to reduce LOS for TSA with the introduction of ERAS.

402 As with all types of surgery, procedure-specific guidance
403 will be required for ERAS in TSA, whereby principles from
404 THA/TKA are adapted and added to TSA. One such exam-
405 ple is in the multimodal pain management strategies that
406 have been successfully adapted and implemented in TSA
407 pathways [58, 59]. Routman et al. [60] found that the addi-
408 tion of intravenous dexamethasone and liposomal bupiva-
409 caine injections to the surgical site intraoperatively in
410 patients undergoing TSA under general anesthesia, with a
411 single-injection interscalene block, reduced median LOS
412 from 2 days to 1 day, with reductions in pain and the need for
413 opioids. As with other orthopedic surgeries, conflicting
414 results have been found on the most effective combination of
415 regional blocks [61, 62] in total shoulder arthroplasty (TSA).

416 A US retrospective study [63] matched 136 TSA patients
417 in a tertiary referral center (TRC) to 136 patients at an ortho-
418 pedic specialty hospital (OSH) with protocols similar to
419 ERAS. They found that although readmission rates were
420 similar, the OSH had a lower LOS than the TRC
421 (1.3 ± 0.5 days vs 1.9 ± 0.6 days, $p < 0.001$). Previously a
422 study in Germany [64] had introduced ERAS concepts in
423 areas such as pain management, drainage and catheter man-
424 agement, physiotherapy, and early mobilization and found
425 improvements in LOS and patient and staff satisfaction.

426 Recent research, mostly retrospective, also indicates that
427 outpatient TSA, implementing ERAS concepts such as mul-
428 timodal pain strategies and minimizing blood loss, is feasible
429 in appropriately selected patients [65, 66].

Ankle Arthroplasty

430 Until recently arthrodesis has been the routine treatment for
431 end-stage osteoarthritis of the ankle. However total ankle
432 arthroplasty (TAA) is now becoming more common with the
433 introduction of better surgical techniques and training and a
434 third generation of three-component mobile-bearing implants
435 [67, 68]. Hospital Episodes Statistics (HES) data from NHS
436 Trusts in England from April 2015 to March 2016 show that
437 the mean LOS for TAA was 3.3 days, with a staggering range
438 of 17.3 days between the hospitals with the minimum and
439 maximum mean LOS [69]. The range of case mix-adjusted
440 expected LOS was just 3.7 days, suggesting that those hospi-
441 tals with a longer LOS were not outliers due to case mix but
442 due to the pathway of care, and so therefore improvements
443 may be possible with the introduction of ERAS.

444 There is little in the literature on the application of ERAS
445 concepts to TAA. However, there is some evidence support-
446 ing the use of regional anesthesia and analgesia over sys-
447 temic opioids [70–72], and pain management is a vital
448 consideration in TAA patients. However, as yet there is lim-
449 ited evidence on multimodal pain management as part of
450 ERAS pathways for TAA. One recent small study gave
451 patients 30–50 ml of bupivacaine as local infiltration anal-
452 gesia (LIA) intraoperatively as part of a newly introduced
453 ERAS pathway. LOS reduced from 3.6 to 2.3 days, and
454 there was a significant improvement in pain scores follow-
455 ing the introduction of the new pathway [73]. There have
456 been some small retrospective studies on outpatients under-
457 going TAA that have used a single-shot popliteal block with
458 ropivacaine followed by periarticular liposomal bupivacaine
459 at the end of the surgery [74] or a popliteal and saphenous
460 nerve block prior to surgery [75]; however further research
461 is required in this area.

462 These studies therefore provide evidence to suggest that
463 outpatient TAA can be successful for selected patients, if
464 teams are experienced and if there is a good postoperative
465 support network [75, 76]. Further work is required, espe-
466 cially within rehabilitation where discharge can be delayed
467 due to social/home circumstances, and post-discharge reha-
468 bilitation improvements are required in order to expedite
469 return to functional activities.
470

Spinal Surgery

471 The demand for complex spinal surgery is increasing [77,
472 78] and may be undertaken within both orthopedic and neu-
473 rosurgical settings. Wide variations in LOS, complications
474 rates, postoperative pain, and functional recovery are
475 reported [77, 79], and so, as for TSA and TAA surgeries,
476 there are strong clinical and economics arguments to improve
477

478 outcomes for spinal surgery by implementing ERAS
479 principles.

480 There is little evidence as yet published on the imple-
481 mentation of ERAS pathways in spinal surgery [80]. The
482 introduction of a novel minimally invasive surgical
483 approach with ERAS components [81] for 42 patients
484 undergoing one- or two-level spinal fusion was found to
485 be successful. A quality improvement study [82] exam-
486 ined the development of an ERAS pathway in an elective
487 spinal service, in a hospital experienced in implementing
488 ERAS for hip and knee arthroplasty patients. The service
489 included more complex procedures, such as posterior sco-
490 liosis correction. ERAS components of the pathway
491 included a leaflet describing what to expect following sur-
492 gery, carbohydrate drinks, laxatives, minimally invasive
493 surgical techniques, the use of tranexamic acid for longer
494 operations, and an estimated discharge date. Standardized
495 multimodal anesthetic and analgesic regimens were
496 implemented, avoiding large doses of intraoperative opi-
497 oids. The ERAS pathway was successful with overall
498 mean LOS reduced by 3 days to 3 days and readmissions
499 reduced to 3% from 7%. In addition, nearly all patients
500 rated their satisfaction with the pathway as good or excel-
501 lent. Studies have also shown that ERAS pathways can be
502 successfully implemented for adolescent idiopathic scoli-
503 osis surgery [83, 84].

504 These initial successes indicate that ERAS pathways
505 should be applicable to all spinal surgery patients, although
506 there is a need for spinal-specific guidelines to enable more
507 widespread adoption. These guidelines need to allow for
508 adaptation to different procedures and the varying levels of
509 preoperative disability and pain [42]. A dedicated chapter on
510 spinal surgery and neurosurgery, providing more details of
511 this patient group, can be found in this book.

512 Conclusion

513 This chapter has detailed that ERAS is a proven and widely
514 adopted technique for improving outcomes in hip and knee
515 arthroplasty. While outcomes have improved dramatically
516 in the last 10 years, challenges remain in order to achieve
517 widespread adoption and implementation of what is already
518 known, and there are future research challenges in order to
519 improve our understanding of the pathophysiology of fac-
520 tors effecting recovery, such as the inflammatory response
521 and pain, and the most effective rehabilitation regimes. The
522 new ERAS Guidelines will hopefully help to bridge both the
523 implementation gap for those new to ERAS and help to con-
524 solidate the current heterogeneous evidence base, where
525 direct comparison of ERAS components is difficult with so
526 many differences to the ERAS pathways currently used. The
527 application and development of ERAS in other elective and

emergency orthopedic procedures is an exciting and emerg- 528
ing area that looks set to bring the benefits of ERAS to even 529
more patients. 530

References 531

1. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after sur- 532
gery: a review. *JAMA Surg.* 2017;152(3):292–8. 533
2. Husted H, Solgaard S, Hansen TB, Soballe K, Kehlet H. Care prin- 534
ciples at four fast-track arthroplasty departments in Denmark. *Dan*
Med Bull. 2010;57(7):A4166. 535
536
3. Campbell J, McDonald D, Smith R, James K, Musculoskeletal 537
Audit. Optimal patient pathways for hip and knee arthroplasties:
Use of Enhanced Recovery After Surgery principles – 2013. A 538
report from the Musculoskeletal Audit on behalf of the Scottish
Government.: National Services Scotland; 2013 [August 21, 2018]; 541
Available from: [http://www.qihub.scot.nhs.uk/media/576341/](http://www.qihub.scot.nhs.uk/media/576341/orthopaedics%20-%20sosdg%20-%20enhanced%20recovery%20-%20msk%20audit%204%20-%20report%20-%20march%202014.pdf)
[orthopaedics%20-%20sosdg%20-%20enhanced%20recovery%20-%20msk%20audit%204%20-%20report%20-%20march%202014.pdf](http://www.qihub.scot.nhs.uk/media/576341/orthopaedics%20-%20sosdg%20-%20enhanced%20recovery%20-%20msk%20audit%204%20-%20report%20-%20march%202014.pdf). 542
543
544
545
4. McDonald DA, Siegmeth R, Deakin AH, Kinninmonth AW, Scott 546
NB. An enhanced recovery programme for primary total knee
arthroplasty in the United Kingdom—follow up at one year. *Knee.* 547
2012 Oct;19(5):525–9. 548
549
5. Wainwright T, Middleton R. An orthopaedic enhanced recovery 550
pathway. *Curr Anaesth Crit Care.* 2010;21(3):114–20. 551
6. Gromov K, Kjaersgaard-Andersen P, Revald P, Kehlet H, Husted 552
H. Feasibility of outpatient total hip and knee arthroplasty in
unselected patients. *Acta Orthop.* 2017;88(5):516–21. 553
554
7. Hoffmann JD, Kusnezov NA, Dunn JC, Zarkadis NJ, Goodman GP, 555
Berger RA. The shift to same-day outpatient joint arthroplasty: a
systematic review. *J Arthroplast.* 2018;33(4):1265–74. 556
557
8. Lazić S, Boughton O, Kellett CF, Kader DF, Villet L, Riviere 558
C. Day-case surgery for total hip and knee replacement: how safe
and effective is it? *EFORT Open Rev.* 2018;3(4):130–5. 559
560
9. Kehlet H. Fast-track hip and knee arthroplasty. *Lancet.* 561
2013;381(9878):1600–2. 562
10. Khan SK, Malviya A, Muller SD, Carluke I, Partington PF, 563
Emmerson KP, et al. Reduced short-term complications and mor-
tality following enhanced recovery primary hip and knee arthro- 564
plasty: results from 6,000 consecutive procedures. *Acta Orthop.* 565
2014;85(1):26–31. 566
567
11. Glassou EN, Pedersen AB, Hansen TB. Risk of re-admission, reop- 568
eration, and mortality within 90 days of total hip and knee arthro-
plasty in fast-track departments in Denmark from 2005 to 2011. 569
Acta Orthop. 2014;85(5):493–500. 570
571
12. Jorgensen CC, Kjaersgaard-Andersen P, Solgaard S, Kehlet H. Hip 572
dislocations after 2,734 elective unilateral fast-track total hip
arthroplasties: incidence, circumstances and predisposing factors. 573
Arch Orthop Trauma Surg. 2014;134(11):1615–22. 574
575
13. Jorgensen CC, Kehlet H. Fall-related admissions after fast-track 576
total hip and knee arthroplasty – cause of concern or consequence
of success? *Clin Interv Aging.* 2013;8:1569–77. 577
578
14. Savaridas T, Serrano-Pedraza I, Khan SK, Martin K, Malviya 579
A, Reed MR. Reduced medium-term mortality following pri-
mary total hip and knee arthroplasty with an enhanced recovery 580
program. A study of 4,500 consecutive procedures. *Acta Orthop.* 581
2013;84(1):40–3. 582
583
15. Larsen K, Hansen TB, Soballe K, Kehlet H. Patient-reported out- 584
come after fast-track hip arthroplasty: a prospective cohort study.
Health Qual Life Outcomes. 2010;8:144. 585
586
16. Larsen K, Hansen TB, Soballe K, Kehlet H. Patient-reported out- 587
come after fast-track knee arthroplasty. *Knee Surg Sports Traumatol*
Arthrosc. 2012;20(6):1128–35. 588
589

- 590 17. Jones EL, Wainwright TW, Foster JD, Smith JR, Middleton RG, Francis NK. A systematic review of patient reported outcomes and patient experience in enhanced recovery after orthopaedic surgery. *Ann R Coll Surg Engl.* 2014;96(2):89–94. 591 592 593
- 594 18. Luna IE, Kehlet H, Peterson B, Wede HR, Hoevsgaard SJ, Aasvang EK. Early patient-reported outcomes versus objective function after total hip and knee arthroplasty: a prospective cohort study. *Bone Joint J.* 2017;99-B(9):1167–75. 595 596 597
- 598 19. Kjellberg J, Kehlet H. A nationwide analysis of socioeconomic outcomes after hip and knee replacement. *Dan Med J.* 2016;63(8):pii: A5257. 599 600
- 601 20. Almeida GJ, Khoja SS, Piva SR. Physical activity after total joint arthroplasty: a narrative review. *Open Access J Sports Med.* 2018;9:55–68. 602 603
- 604 21. Hammett T, Simonian A, Austin M, Butler R, Allen KD, Ledbetter L, et al. Changes in physical activity after Total hip or knee arthroplasty: a systematic review and meta-analysis of six- and twelve-month outcomes. *Arthritis Care Res (Hoboken).* 2018;70(6):892–901. 605 606 607 608
- 609 22. Smith T, Withers T, Luben R, Sackley C, Jones A, MacGregor A. Changes in physical activity following total hip or knee arthroplasty: a matched case-control study from the EPIC-Norfolk cohort. *Clin Rehabil.* 2017;31(11):1548–57. 610 611 612
- 613 23. Culliford D. The past, present and future of total hip and knee arthroplasty in the UK: a population-based statistical analysis [Doctoral]: University of Southampton; 2016. 614 615
- 616 24. Stowers MD, Lemanu DP, Hill AG. Health economics in enhanced recovery after surgery programs. *Can J Anaesth.* 2015;62(2):219–30. 617 618
- 619 25. Andreasen SE, Holm HB, Jorgensen M, Gromov K, Kjaersgaard-Andersen P, Husted H. Time-driven activity-based cost of fast-track total hip and knee arthroplasty. *J Arthroplast.* 2017;32(6):1747–55. 620 621
- 622 26. Akhavan S, Ward L, Bozic KJ. Time-driven activity-based costing more accurately reflects costs in arthroplasty surgery. *Clin Orthop Relat Res.* 2016;474(1):8–15. 623 624
- 625 27. Chen A, Sabharwal S, Akhtar K, Makaram N, Gupte CM. Time-driven activity based costing of total knee replacement surgery at a London teaching hospital. *Knee.* 2015;22(6):640–5. 626 627
- 628 28. Wainwright TW, Burgess LC. To what extent do current total hip and knee replacement patient information resources adhere to enhanced recovery after surgery principles? *Physiotherapy.* 2018;104(3):327–37. 629 630
- 631 29. Wainwright T, Burgess L. Is ERAS now the routine standard care in English NHS Hospitals for total hip replacement and total knee replacement? *Clin Nutr ESPEN.* 2018;25:199. 632 633
- 634 30. Kehlet H. ERAS implementation-time to move forward. *Ann Surg.* 2018;267(6):998–9. 635 636
- 637 31. Dort JC, Farwell DG, Findlay M, Huber GF, Kerr P, Shea-Budgell MA, et al. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society. *JAMA Otolaryngol Head Neck Surg.* 2017;143(3):292–303. 638 639 640
- 641 32. Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, Hubner M, et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS((R))) society recommendations. *Clin Nutr.* 2013 Dec;32(6):879–87. 642 643 644 645
- 646 33. Lassen K, Coolsen MM, Slim K, Carli F, de Aguilar-Nascimento JE, Schafer M, et al. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(R)) society recommendations. *World J Surg.* 2013;37(2):240–58. 647 648 649
- 650 34. Melloul E, Hubner M, Scott M, Snowden C, Prentis J, Dejong CH, et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) society recommendations. *World J Surg.* 2016;40(10):2425–40. 651 652 653
- 654 35. Mortensen K, Nilsson M, Slim K, Schafer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS(R)) society recommendations. *Br J Surg.* 2014;101(10):1209–29. 655 657
- 658 36. Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, et al. Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS((R))) society recommendations. *World J Surg.* 2013;37(2):285–305. 659 660 661
- 662 37. Temple-Oberle C, Shea-Budgell MA, Tan M, Semple JL, Schrag C, Barreto M, et al. Consensus review of optimal perioperative care in breast reconstruction: Enhanced Recovery After Surgery (ERAS) society recommendations. *Plast Reconstr Surg.* 2017;139(5):1056e–71e. 663 664 665 666
- 667 38. Thorell A, MacCormick AD, Awad S, Reynolds N, Roulin D, Demartines N, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) society recommendations. *World J Surg.* 2016;40(9):2065–83. 668 669 670
- 671 39. Ibrahim MS, Twaij H, Giebaly DE, Nizam I, Haddad FS. Enhanced recovery in total hip replacement: a clinical review. *Bone Joint J.* 2013;95-B(12):1587–94. 672 673
- 674 40. Ibrahim MS, Alazzawi S, Nizam I, Haddad FS. An evidence-based review of enhanced recovery interventions in knee replacement surgery. *Ann R Coll Surg Engl.* 2013;95(6):386–9. 675 676 677
- 678 41. Sprowson A, McNamara I, Manktelow A. (v) Enhanced recovery pathway in hip and knee arthroplasty: “fast track” rehabilitation. *Orthop Trauma.* 2013;27(5):296–302. 679 680
- 681 42. Wainwright TW, Wang MY, Immins T, Middleton RG. Enhanced recovery after surgery (ERAS)—concepts, components, and application to spine surgery. *Semin Spine Surg.* 2018;30(2):104–10. 682 683
- 684 43. Wainwright TW, Gill M, et al. Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. In review. 685 686AU2
- 687 44. Kehlet H, Jorgensen CC. Advancing surgical outcomes research and quality improvement within an enhanced recovery program framework. *Ann Surg.* 2016;264(2):237–8. 688 689
- 690 45. Wainwright TW, Kehlet H. Fast-track hip and knee arthroplasty - have we reached the goal? *Acta Orthop.* 2019;90(1):3–5. 691 692
- 693 46. Lindberg-Larsen V, Kehlet H, Pilely K, Bagger J, Rovsing ML, Garred P. Preoperative methylprednisolone increases plasma Pentraxin 3 early after total knee arthroplasty: a randomized, double-blind, placebo-controlled trial. *Clin Exp Immunol.* 2018;191(3):356–62. 694 695 696
- 697 47. Gilron I, Carr DB, Desjardins PJ, Kehlet H. Current methods and challenges for acute pain clinical trials. *Pain Rep.* 2018;4(3):e647. 698 699
- 700 48. Bandholm T, Wainwright TW, Kehlet H. Rehabilitation strategies for optimisation of functional recovery after major joint replacement. *J Exp Orthop.* 2018;5(1):44. 701 702
- 703 49. Wainwright TW, Immins T, Middleton RG. Enhanced recovery after surgery: an opportunity to improve fractured neck of femur management. *Ann R Coll Surg Engl.* 2016;98(7):500–6. 704 705
- 706 50. Egerod I, Rud K, Specht K, Jensen PS, Trangbaek A, Ronfelt I, et al. Room for improvement in the treatment of hip fractures in Denmark. *Dan Med Bull.* 2010;57(12):A4199. 707 708
- 709 51. Holt PJ, Sinha S, Ozdemir BA, Karthikesalingam A, Poloniecki JD, Thompson MM. Variations and inter-relationship in outcome from emergency admissions in England: a retrospective analysis of hospital episode statistics from 2005–2010. *BMC Health Serv Res.* 2014;14:270. 710 711 712
- 713 52. Guay J, Parker MJ, Griffiths R, Kopp S. Peripheral nerve blocks for hip fractures. *Cochrane Database Syst Rev.* 2017;5:CD001159. 714 715
- 716 53. Gilchrist N, Dalzell K, Pearson S, Hooper G, Hoeben K, Hickling J, et al. Enhanced hip fracture management: use of statistical methods and dataset to evaluate a fractured neck of femur fast track pathway-pilot study. *N Z Med J.* 2017;130(1455):91–101. 717 718
- 719 54. Haugan K, Johnsen LG, Basso T, Foss OA. Mortality and readmission following hip fracture surgery: a retrospective study comparing conventional and fast-track care. *BMJ Open.* 2017;7(8):e015574. 720 721

- 722 55. Day JS, Lau E, Ong KL, Williams GR, Ramsey ML, Kurtz
723 SM. Prevalence and projections of total shoulder and elbow
724 arthroplasty in the United States to 2015. *J Shoulder Elb Surg.*
725 2010;19(8):1115–20.
- 726 56. Hospital Episode Statistics (HES). NHS Digital; [August 30,
727 2018]; Available from: [https://digital.nhs.uk/data-and-information/
728 data-tools-and-services/data-services/hospital-episode-statistics](https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics).
- 729 57. Wainwright TW, Immins T, Antonis J, et al. Enhanced Recovery
730 after Surgery (ERAS): Concepts and application to total shoulder
731 replacement. *Orthop Nurs.* In Review.
- 732 58. Codding JL, Getz CL. Pain management strategies in shoulder
733 arthroplasty. *Orthop Clin North Am.* 2018;49(1):81–91.
- 734 59. Huang Y, Chiu F, Webb CA, Weyker PD. Review of the evi-
735 dence: best analgesic regimen for shoulder surgery. *Pain Manag.*
736 2017;7(5):405–18.
- 737 60. Routman HD, Israel LR, Moor MA, Boltuch AD. Local injection of
738 liposomal bupivacaine combined with intravenous dexamethasone
739 reduces postoperative pain and hospital stay after shoulder arthro-
740 plasty. *J Shoulder Elb Surg.* 2017;26(4):641–7.
- 741 61. Chalmers PN, Salazar D, Fingerman ME, Keener JD, Chamberlain
742 A. Continuous interscalene brachial plexus blockade is associated
743 with reduced length of stay after shoulder arthroplasty. *Orthop
744 Traumatol Surg Res.* 2017;103(6):847–52.
- 745 62. Thompson M, Simonds R, Clinger B, Kobulnicky K, Sima AP,
746 Lahaye L, et al. Continuous versus single shot brachial plexus
747 block and their relationship to discharge barriers and length of stay.
748 *J Shoulder Elb Surg.* 2017;26(4):656–61.
- 749 63. Padegimas EM, Zmistowski BM, Clyde CT, Restrepo C, Abboud
750 JA, Lazarus MD, et al. Length of stay after shoulder arthroplasty-
751 the effect of an orthopedic specialty hospital. *J Shoulder Elb Surg.*
752 2016;25(9):1404–11.
- 753 64. Jerosch J, Goddertz J, Herwig M, Linke C, Schwegel P, Lang
754 K. Rapid Recovery – an innovative approach for patients in shoul-
755 der arthroplasty. *OUP.* 2012;1(4):167–72.
- 756 65. Basques BA, Gardner EC, Toy JO, Golinvaux NS, Bohl DD, Grauer
757 JN. Length of stay and readmission after Total shoulder arthro-
758 plasty: an analysis of 1505 cases. *Am J Orthop (Belle Mead NJ).*
759 2015;44(8):E268–71.
- 760 66. Brolin TJ, Mulligan RP, Azar FM, Throckmorton TW. Neer Award
761 2016: outpatient total shoulder arthroplasty in an ambulatory sur-
762 gery center is a safe alternative to inpatient total shoulder arthro-
763 plasty in a hospital: a matched cohort study. *J Shoulder Elb Surg.*
764 2017;26(2):204–8.
- 765 67. Easley ME, Adams SB Jr, Hembree WC, DeOrio JK. Results
766 of total ankle arthroplasty. *J Bone Joint Surg Am.*
767 2011;93(15):1455–68.
- 768 68. Zaidi R, Cro S, Gurusamy K, Siva N, Macgregor A, Henricson A,
769 et al. The outcome of total ankle replacement: a systematic review
770 and meta-analysis. *Bone Joint J.* 2013;95-B(11):1500–7.
69. Wainwright TW, Immins T, Antonis JHA, Taylor H, Middleton
771 RG. Can the introduction of Enhanced Recovery After Surgery
772 (ERAS) reduce the variation in length of stay after total ankle
773 replacement surgery? *Foot Ankle Surg.* 2017;25(3):294–7.
- 774 70. DeOrio JK, Gadsden J. Total ankle arthroplasty and perioperative
775 pain. *J Surg Orthop Adv.* 2014;23(4):193–7.
- 776 71. Gallardo J, Lagos L, Bastias C, Henriquez H, Carcuro G, Paleo
777 M. Continuous popliteal block for postoperative analgesia in total
778 ankle arthroplasty. *Foot Ankle Int.* 2012;33(3):208–12.
- 779 72. Young DS, Cota A, Chaytor R. Continuous infragluteal sciatic
780 nerve block for postoperative pain control after total ankle arthro-
781 plasty. *Foot Ankle Spec.* 2014;7(4):271–6.
- 782 73. Jain K, Murphy P, Karim T, Karski M, Clough TM. Results of
783 enhanced recovery after primary ankle replacements. *Foot (Edinb).*
784 2017;31:13–5.
- 785 74. Mulligan RP, Morash JG, DeOrio JK, Parekh SG. Liposomal bupi-
786 vacaine versus continuous popliteal sciatic nerve block in total
787 ankle arthroplasty. *Foot Ankle Int.* 2017;38(11):1222–8.
- 788 75. Gonzalez T, Fisk E, Chiodo C, Smith J, Bluman EM. Economic
789 analysis and patient satisfaction associated with outpatient total
790 ankle arthroplasty. *Foot Ankle Int.* 2017;38(5):507–13.
- 791 76. Mulligan RP, Parekh SG. Safety of outpatient total ankle arthro-
792 plasty vs traditional inpatient admission or overnight observation.
793 *Foot Ankle Int.* 2017;38(8):825–31.
- 794 77. Deyo RA, Mirza SK, Martin BI, Kreuter W, Goodman DC, Jarvik
795 JG. Trends, major medical complications, and charges associated
796 with surgery for lumbar spinal stenosis in older adults. *JAMA.*
797 2010;303(13):1259–65.
- 798 78. Katz JN. Lumbar spinal fusion. Surgical rates, costs, and complica-
799 tions. *Spine (Phila Pa 1976).* 1995;20(24 Suppl):78S–83S.
- 800 79. Rushton A, White L, Heap A, Heneghan N. Evaluation of current
801 surgeon practice for patients undergoing lumbar spinal fusion sur-
802 gery in the United Kingdom. *World J Orthop.* 2015;6(6):483–90.
- 803 80. Wainwright TW, Immins T, Middleton RG. Enhanced recovery
804 after surgery (ERAS) and its applicability for major spine surgery.
805 *Best Pract Res Clin Anaesthesiol.* 2016;30(1):91–102.
- 806 81. Development of an Enhanced Recovery After Surgery (ERAS)
807 approach for lumbar spinal fusion. *J Neurosurg Spine.*
808 2017;26(4):411–8.
- 809 82. Blackburn J, Madhaven P, Leung YL, Walburn M. An enhanced
810 recovery program for elective spinal surgery patients. *J Clin
811 Outcomes Manag.* 2016;23(10):462–9.
- 812 83. Gornitzky AL, Flynn JM, Muhly WT, Sankar WN. A rapid recov-
813 ery pathway for adolescent idiopathic scoliosis that improves pain
814 control and reduces time to inpatient recovery after posterior spinal
815 fusion. *Spine Deform.* 2016;4(4):288–95.
- 816 84. Muhly WT, Sankar WN, Ryan K, Norton A, Maxwell LG,
817 DiMaggio T, et al. Rapid recovery pathway after spinal fusion for
818 idiopathic scoliosis. *Pediatrics.* 2016;137(4):e20151568.
- 819